Press Releases
Eisai presents Non-Clinical Research Findings in 107th Annual Meeting of American Association for Cancer Research
Enhanced Mechanism Of Angiogenesis Inhibition And Anti-Tumor Activity In Renal Cell Carcinoma Investigated World pharma today/Press releases /-Eisai Co Ltd. announced that it has presented the results of non-clinical research investigating the combination of Eisai's in-house...
Press Releases
Baxter Receives Marketing Authorization of Nutrition for Preterm Newborns in UK and Denmark
Baxter International Inc announced it has received Marketing Authorization from the Competent Authorities in the United Kingdom and Denmark for NUMETA G13E 300 mL, a parenteral (intravenous) nutrition (PN) product. These national approvals are the first of 20 European...
Press Releases
Merck Receives Breakthrough Therapy Designation from U.S. FDA for KEYTRUDA® in Classical Hodgkin Lymphoma (cHL)
Merck known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with relapsed...
Press Releases
Bayer to present latest preclinical data on oncology compounds in 107th Annual Meeting of American Association for Cancer Research
Bayer will present latest preclinical data on oncology compounds, which are currently in preclinical or early clinical development stage at the American Association for Cancer Research (AACR) 107th Annual Meeting, April 16-20, 2016, in New Orleans, LA. ...
Press Releases
Kanuma receives marketing approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency
Alexion Pharmaceuticals, Inc announced that Japan’s Ministry of Health, Labour and Welfare has approved Kanuma for the treatment of patients of all ages in Japan with lysosomal acid lipase deficiency. Kanuma, an innovative enzyme replacement therapy...
Press Releases
Phase 3 Study Findings Demonstrate Treatment With Baricitinib Results In Significant Improvements For Patients With Rheumatoid Arthritis Who Had Inadequate Response To Biologics
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment currently under regulatory review for the treatment of moderate-to-severe...
Press Releases
Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential for Genotype-Agnostic and Combination Therapies for People with Cystic Fibrosis
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing. such as cystic fibrosis (CF), today announced new preclinical data on the company’s first-in-class genotype-agnostic...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read